Document is current
Any future updates will be listed below
-
Authors
Leblanc, Andréanne
Beltran-Bless, Ana-Alicia
Pond, Gregory R.
El Emam, Khaled
Juwara, Lamin
Clemons, Lucas
Bayani, Jane
Pilgram, Lisa
Pharoah, Paul
Mallon, Elizabeth
Taylor, Karen J.
Markopoulos, Christos
Dirix, Luc
Vandermeer, Lisa
Hilton, John
Savard, Marie France
Bartlett, John M. S.
Clemons, Mark
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00279448 at ClinicalTrials.govnct00032136 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
https://doi.org/10.1016/j.radonc.2013.08.020
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy
https://doi.org/10.1007/s10549-026-07909-5
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
https://doi.org/10.1016/s0140-6736(10)62312-4
nct00036270 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
https://doi.org/10.1016/j.radonc.2013.08.020
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy
https://doi.org/10.1007/s10549-026-07909-5
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
https://doi.org/10.1016/s0140-6736(10)62312-4
Documents that mention this clinical trial
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
https://doi.org/10.1016/j.radonc.2013.08.020
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy
https://doi.org/10.1007/s10549-026-07909-5
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
https://doi.org/10.1016/s0140-6736(10)62312-4
- License Information
-
More Information
Article History
Received: 20 November 2025
Accepted: 27 January 2026
First Online: 5 February 2026
Declarations
:
: A.L has no relevant financial or non-financial interests to disclose. A-A.B-B has no relevant financial or non-financial interests to disclose. G.R.P. has received consultancy from Takeda, Merck, Profound Medical and honoraria from AstraZeneca. Also has a close family member who is employed by Roche Canada and who owns stock in Roche Ltd. J.B has received honoraria from Thermo Fisher Scientific, Nanostring Technologies and research funding from Thermo Fisher Scientific.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ottawa Hospital Science Network Research Ethics Board (OHSN-REB 20210493-01H) and the University of Toronto (REB# 35339).
